Patents by Inventor Robert F. Reder
Robert F. Reder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9642850Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: GrantFiled: November 15, 2016Date of Patent: May 9, 2017Assignee: PURDUE PHARMA L.P.Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Publication number: 20170056393Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: ApplicationFiled: November 15, 2016Publication date: March 2, 2017Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Publication number: 20160220559Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: ApplicationFiled: September 8, 2015Publication date: August 4, 2016Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Publication number: 20150157625Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: ApplicationFiled: July 15, 2014Publication date: June 11, 2015Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Publication number: 20140073663Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: ApplicationFiled: November 14, 2013Publication date: March 13, 2014Applicant: PURDUE PHARMA L.P.Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Publication number: 20110288112Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: ApplicationFiled: September 22, 2010Publication date: November 24, 2011Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Patent number: 6699908Abstract: Methods and formulations for inducing substantially safer local anesthesia in a patient are provided. The methods comprise administering, to a patient in need thereof, a substrate containing a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material to safely obtain a reversible nerve blockade when implanted or injected in a patient.Type: GrantFiled: September 26, 2001Date of Patent: March 2, 2004Assignee: Euro-Celtique, S.A.Inventors: Richard S. Sackler, Paul D. Goldenheim, Mark Chasin, Ronald M. Burch, Robert F. Reder, Joseph Tigner
-
Publication number: 20030198675Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: ApplicationFiled: March 28, 2003Publication date: October 23, 2003Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Publication number: 20030091631Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: ApplicationFiled: December 27, 2001Publication date: May 15, 2003Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Publication number: 20020114835Abstract: Methods and formulations for inducing substantially safer local anesthesia in a patient are provided. The methods comprise administering, to a patient in need thereof, a substrate containing a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material to safely obtain a reversible nerve blockade when implanted or injected in a patient.Type: ApplicationFiled: September 26, 2001Publication date: August 22, 2002Inventors: Richard S. Sackler, Paul D. Goldenheim, Mark Chasin, Ronald M. Burch, Robert F. Reder, Joseph Tigner
-
Patent number: 6344212Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: GrantFiled: January 8, 2001Date of Patent: February 5, 2002Assignee: Euro-Celtique S.A.Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
-
Publication number: 20010002259Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: ApplicationFiled: January 8, 2001Publication date: May 31, 2001Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
-
Patent number: 6231886Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: GrantFiled: May 14, 1999Date of Patent: May 15, 2001Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Patent number: 5968547Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: GrantFiled: September 29, 1997Date of Patent: October 19, 1999Assignee: Euro-Celtique, S.A.Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
-
Patent number: RE41408Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: GrantFiled: May 1, 2007Date of Patent: June 29, 2010Assignee: Purdue Pharma L.P.Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
-
Patent number: RE41489Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: GrantFiled: May 1, 2007Date of Patent: August 10, 2010Assignee: Purdue Pharma L.P.Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
-
Patent number: RE41571Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.Type: GrantFiled: May 1, 2007Date of Patent: August 24, 2010Assignee: Purdue Pharma L.P.Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
